Recombinant human erythropoietin: Effects on frataxin expression in vitro

European Journal of Clinical Investigation

Volumn 35, Issue 11, 2005, Pages 711-717

  Sturm, B ^a   Stupphann, D ^a   Kaun, C ^b   Boesch, S ^c   Schranzhofer, M ^d   Wojta, J ^b   Goldenberg, H ^a   Scheiber Mojdehkar, Barbara ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d Institute of Medical Biochemistry   (Austria)

Author keywords

Frataxin; Friedreich's ataxia; Recombinant human erythropoietin

Indexed keywords

FRATAXIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBROBLAST; FRIEDREICH ATAXIA; HEART MUSCLE CELL; HEART TRANSPLANTATION; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IRON STORAGE; LYMPHOCYTE; MOUSE; NERVE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL LINE; CELLS, CULTURED; ERYTHROPOIETIN, RECOMBINANT; FIBROBLASTS; FRIEDREICH ATAXIA; HUMANS; IRON-BINDING PROTEINS; LYMPHOCYTES; MYOCYTES, CARDIAC; NEURONS;

EID: 27844526573     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01568.x     Document Type: Article

References (38)

1. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981;104:589-620.
2. Mateo I, Llorca J, Volpini V, Corral J, Berciano J, Combarros O et al. GAA repeats and clinical variation in Friedreich's ataxia. Acta Neurol Scand 2004;109:75-8.
3. Campuzano V, Contermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-7.
4. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S. Frataxin is reduced in Friedreich's ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997;6:1771-80.
5. Tan G, Chen LS, Lonnerdal B, Gellera C, Taroni FA, Cortopassi GA. Frataxin expression rescues mitochondrial dysfunctions in FA cells. Hum Mol Gen 2001;19:2099-107.
6. Napier I, Ponka P, Richardson DR. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 2005;105:1867-74.
7. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 2001;27:181-6.
8. Sturm B, Bistrich U, Schranzhofer M, Sarsero JP, Rauen U, Scheiber-Mojdehkar B et al. Friedreich's ataxia: no changes in mitochondrial labile iron in human lymphocytes and fibroblasts A decrease in antioxidative capacity? J Biol Chem 2005;280:6701-8.
9. Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, Schapira AHV. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum Mol Gen 2000;9:275-82.
10. Bulteau AL, O'Neill HA, Kennedy MC, Ikeda-Saito M, Isaya G, Szweda LI. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 2004;305:242-4.
11. Wilson RB, Lynch DR, Farmer JM, Brooks DG, Fischbeck KH. Increased serum transferrin receptor concentrations in Friedreich's ataxia. Ann Neurol 2000;47:659-61.
12. Scarano V, de Cristofaro T, De Michele G, Salvatore E, De Biase I, Monticelli A et al. Serum transferrin receptor levels in Friedreich's and other degenerative ataxias. Neurology 2001;57:159-60.
13. Sitte K, Zaibak F, Delatycki MB, Ioannou PA. Normal levels of soluble transferrin receptor in Friedreich's ataxia. Clin Genet 2002;62:250-1.
14. Wilson RB, Lynch DR, Fischbeck KH. Normal serum iron and ferritin concentrations in patients with Friedreich's ataxia. Ann Neural 1998;44:132-4.
15. Zhang Y, Lyver ER, Knight SAB, Lesuisse E, Dancis A. Frataxin and mitochondrial carrier proteins, Mrs3p and Mrs4p, cooperate in providing iron for heme synthesis. J Biol Chem 2005;280:19794-807.
16. Seznec H, Simon D, Monassier L, Criqui-Filipe P, Gansmuller A, Rustin P et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 2004;13:1017-24.
17. Sarsero JP, Li L, Wardan H, Sitte K, Williamson R, Ioannou PA. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich's ataxia. J Gene Med 2003;5:72-81.
18. Turano M, Tammaro A, De Biase I, Lo Casale MS, Ruggiero G, Monticelli A. 3-Nitropropionic acid increases frataxin expression in human lymphocytes and in transgenic rat PC12 cells. Neurosi Lett 2003;350:184-6.
19. Ghazizadeh M. Cisplatin may induce frataxin expression. J Nippon Med Sch 2003;70:367-71.
20. Li W, Maeda Y, Rong Yuang R, Elkabes S, Cook S, Dowling P. Beneficial Effect of Erythropoietin on Experimental Allergic Encephalomyelitis. Ann Neurol 2004;56:767-77.
21. Sirén AL, Ehrenreich H. Erythropoietin-a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001;251:179-84.
22. Juul S. Erythropoietin in the central nervous system and its use to prevent hypo-ischemic brain damage. Acta Paediatr Suppl 2002;91:36-42.
23. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:538-48.
24. Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovascular Res 2004;63:208-16.
25. Macfelda K, Weiss TW, Kaun C, Breuss JM, Zorn G, Oberndorfer U et al. Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1 alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 2002;34:1681-91.
26. Santos MM, Ohshima K, Pandolfo M. Frataxin deficiency enhances apoptosis in cells differentiating into neuroectoderm. Hum Mol Genet 2001;10:1935-44.
27. Pianese L, Turano M, Lo Casale MS, De Biase I, Giacchetti M, Ponticelli A et al. Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich's ataxia patients and carriers. J Neurol Neurosurg Psychiatry 2004;75:1061-3.
28. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S et al. Frataxin is reduced in Friedreich's ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997;6:1771-80.
29. Cerami A, Brines M, Grezzi P, Cerami C, Itri LM. Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant 2002;17:8-12.
30. Chung YH, KimSDI SI, Joo KM, Kim YS, Lee WB, Yun KW et al. Age-related changes in erythropoietin immunoreactivity in the cerebral cortex and hippocampus of rats. Brain Res 2004;1018:141-6.
31. Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol 2004;207:3233-42.
32. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95:4635-40.
33. Erbayraktar S, Yilmaz O, Gokmen N, Brines M. Erythropoietin is a multi-functional tissue-protective cytokine. Curr Hematol Rep 2003;2:465-70.
34. Wang L, Zhang ZG, Wang Y, Zhang RL, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004;35:1731-6.
35. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology (AM Soc Hematol Educ Program) 2002;136-61.
36. Sanchez-Casis G, Cote M, Barbeau A. Pathology of the heart in Friedreich's ataxia: review of the literature and report of one case. Can J Neurol Sci 1977;3:349-54.
37. Waldvogel D, van Gelderen P, Hallet M. Increased iron in dendate nucleus of patients with Friedrich's ataxia. Ann Neurol 1999;46:123-5.
38. de Francisco AL, Fernandez Fresnedo G, Rodrigo E, Pinera C, Heras M, Palomar R et al. Past, present and future of erythropoietin use in the elderly, Int Urol Nephrol 2002;33:187-93.